TD Cowen initiated coverage of Kailera Therapeutics (KLRA) with a Buy rating and $57 price target The company’s lead asset ribupatide is “differentiated” from Eli Lilly’s Zepbound because of solid efficacy and better tolerability, the analyst tells investors in a research note. The firm believes ribupatide has “best-in-class potential” with 23% weight loss at 36 weeks in a Chinese Phase 2 study. TD expects a launch in 2029 and models $1.6B in fiscal 3035 sales.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KLRA:
- Kailera Therapeutics initiated with an Outperform at William Blair
- Kailera Therapeutics initiated with an Overweight at JPMorgan
- Kailera Therapeutics initiated with a Buy at Jefferies
- Opening Day: HawkEye 360 jumps in debut after high‑end pricing
- PMV Pharmaceuticals chair Rich Heyman to depart, Laurie Stelzer to succeed